Overview
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.
Last reviewed: 27 July 2022
Next review: We will review this decision if the company decides to make a submission.